Graybug Vision Inc (GRAY): Price and Financial Metrics


Graybug Vision Inc (GRAY): $3.73

0.17 (+4.78%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

GRAY Stock Price Chart Interactive Chart >

Price chart for GRAY

GRAY Price/Volume Stats

Current price $3.73 52-week high $37.88
Prev. close $3.56 52-week low $3.43
Day low $3.52 Volume 144,679
Day high $3.75 Avg. volume 1,035,303
50-day MA $3.97 Dividend yield N/A
200-day MA $11.35 Market Cap 79.39M

Graybug Vision Inc (GRAY) Company Bio


GrayBug is a pharmaceutical company that focuses on developing the next generation of products for the treatment of chronic vision-threatening diseases of the retina and optic nerve. The company is currently developing a continuum of proprietary micro – and nanoparticle controlled release technologies and implants for strategic partnership and its own therapeutic products for major ocular disease indications including wet AMD and Glaucoma. The company was founded in 2011 and headquartered in Baltimore, Maryland.


GRAY Latest News Stream


Event/Time News Detail
Loading, please wait...

GRAY Latest Social Stream


Loading social stream, please wait...

View Full GRAY Social Stream

Latest GRAY News From Around the Web

Below are the latest news stories about Graybug Vision Inc that investors may wish to consider to help them evaluate GRAY as an investment opportunity.

Graybug Vision to Participate in the Cantor Virtual Global Healthcare Conference

BALTIMORE, Sept. 21, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of diseases of the retina and optic nerve, today announced that Fred Guerard, PharmD, Chief Executive Officer of Graybug Vision, will present at the 2021 Cantor Virtual Global Healthcare Conference on Tuesday, September 28, 2021 at 11:20 a.m. ET / 8:20 a.m. PT. Dr. Guerard will provide a corporate update, in

Yahoo | September 21, 2021

A Look at Graybug Vision’s Risk Factors

Graybug Vision (GRAY) is a biotech company that develops transformational therapies for the treatment of retinal and optic nerve illnesses. Let’s take a look at the eye disease drug maker’s latest financial performance and risk factors. (See Graybug Vision stock charts on TipRanks) Graybug Vision’s Financial Performance Graybug Vision reported a net loss of $7.7 million in the second quarter versus a net loss of $5.9 million in the year-ago quarter. General and administrative expenses jumped 157% to $3.6 million, while research and development expenses decreased 8.7% to $4.2 million on a year-over-year basis.

Shalu Saraf on TipRanks | September 10, 2021

Graybug Vision Announces Financial Results for the Three and Six Months Ended June 30, 2021, and Recent Corporate Developments

REDWOOD CITY, Calif., Aug. 11, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of diseases of the retina and optic nerve, today provided an update on recent corporate developments and reported financial results for the three and six months ended June 30, 2021.

Intrado Digital Media | August 11, 2021

Graybug Vision Announces Financial Results for the Three and Six Months Ended June 30, 2021, and Recent Corporate Developments

REDWOOD CITY, Calif., Aug. 11, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of diseases of the retina and optic nerve, today provided an update on recent corporate developments and reported financial results for the three and six months ended June 30, 2021. Recent Corporate Developments Completed six-month extended observation period of ALTISSIMO Phase 2b trial in wet AMD—

Yahoo | August 11, 2021

Graybug Vision to Participate in the 2021 Wedbush PacGrow Healthcare Virtual Conference

REDWOOD CITY, Calif., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of diseases of the retina and optic nerve, today announced that Fred Guerard, PharmD, Chief Executive Officer of Graybug Vision, will participate in a panel discussion titled Goldeneye at the Wedbush PacGrow Healthcare Conference on Wednesday, August 11, 2021 at 9:45 a.m. ET / 6:45 a.m. PT.

Intrado Digital Media | August 4, 2021

Read More 'GRAY' Stories Here

GRAY Price Returns

1-mo -1.06%
3-mo -28.27%
6-mo -36.67%
1-year N/A
3-year N/A
5-year N/A
YTD -87.15%
2020 N/A
2019 N/A
2018 N/A
2017 N/A
2016 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 6.2609 seconds.